Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 21, 2026
TickeronGET DAILY SIGNALS
10x Genomics (TXG): Can It Reach $100 for a +strong performance?

10x Genomics (TXG): Can It Reach $100 for a +strong performance?

Key Takeaways

  • The selected target: $100 per share, a round-number psychological milestone roughly 56% above recent trading levels.
  • Strongest bullish factor: Accelerating adoption of the Atera platform, a 74% gross margin, and raised 2026 revenue guidance of $610–$630 million.
  • Biggest obstacle: The stock already trades above the average analyst price target of about $49–$50, and the company remains unprofitable on a GAAP basis.
  • Key levels: The 52-week high near $64.50 now acts as near-term resistance, while prior breakout zones in the upper $40s to low $50s serve as potential support.
  • Bottom line: Reaching $100 is possible over a longer horizon, but it would require sustained revenue re-acceleration and a significant re-rating beyond current analyst expectations.

Why the $100 Level Stands Out

The $100 stock price target carries special weight because it is a clean psychological threshold rather than a technical measurement. For a company whose shares traded below $12 within the past year, crossing into triple digits would symbolize a full-scale turnaround and cement its place among high-multiple life science growth names. It is also a level that naturally captures retail and institutional attention, making it a frequent subject of search-driven market discussion.

Company Overview

10x Genomics is a life science technology company that develops instruments, consumables, and software used to study biology at single-cell and spatial resolution. Its flagship platforms include the Chromium single-cell system and the Xenium spatial biology instrument, with the newer Atera platform increasingly central to the growth narrative. The company went public in 2019 and carries a market capitalization of roughly $8.3 billion.

Current Market Position

TXG recently traded around $63–$64, near the top of its 52-week range of $11.16 to $64.53. The move reflects a sharp re-rating driven by improving fundamentals rather than broad market drift. The stock's five-year beta of roughly 2.0 underscores its volatility: it can gain or lose ground far faster than the broader market, which cuts both ways when evaluating a target as ambitious as $100.

What Could Drive the Next Leg Higher

Several verified fundamentals support continued upside. In its most recent quarter, the company reported revenue of about $151 million, ahead of expectations, with a non-GAAP loss narrower than forecast. Management raised full-year 2026 revenue guidance to a range of $610–$630 million, citing strong early demand for the Atera platform. Gross margin improved to roughly 74%, signaling that core products are high-margin and scaling efficiently even before the business reaches sustained profitability.

Strategic collaborations — including work with major cancer research institutions on single-cell and spatial tumor profiling — also reinforce the long-term thesis that genomics tools are becoming integral to precision medicine and drug discovery. If these partnerships translate into broader consumable pull-through, revenue growth could re-accelerate and support a higher valuation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Prevent the Move

The primary obstacle is valuation and profitability. The company still reports negative earnings per share, and its price-to-sales multiple sits well into double digits. More notably, the consensus analyst price target stands near $49.50 — below the current share price — with even the most bullish published target at $65. In other words, Wall Street's base-case expectation is that the stock has already priced in much of the near-term good news.

Reaching $100 would require the market to re-rate the stock to a multiple roughly 50% above even the highest current analyst target. That would likely demand not just revenue growth but a credible, visible path to profitability, sustained gross-margin gains, and continued success with Atera against well-funded competitors in the single-cell and spatial biology space.

Analyst Opinions and Price Targets

Following the recent earnings report, several firms raised their targets: Stifel lifted its target to $50, while Canaccord Genuity moved to $60 and Stephens raised its target to $65. Others, including Morgan Stanley, J.P. Morgan, and Citi, remain more cautious with neutral ratings and targets in the $40–$50 range. The dispersion — from roughly $40 to $65 — reflects genuine disagreement about whether the recent momentum can persist. Notably, none of these targets approach $100, meaning the selected objective sits far outside the current analyst consensus and would require a fundamentally different earnings trajectory.

Technical Levels That Matter

From a technical analysis standpoint, the prior 52-week high near $64.50 is the immediate resistance level that must first be cleared and held. A sustained breakout above that zone would remove the last remaining overhang from the stock's recent peak. On the downside, the upper $40s to low $50s — where the stock consolidated before its latest leg higher — represent a meaningful support zone that could act as a floor if momentum fades. The $100 level itself would be the next major psychological resistance, but it is not anchored by prior price history, making it more of an aspirational target than a defined supply zone.

Final Assessment

On balance, a move to $100 appears plausible only over a longer time horizon and would require conditions that are not yet in place. The strongest supports are real: accelerating Atera adoption, a high gross margin, and upwardly revised revenue guidance give the growth story tangible momentum. The largest headwinds are equally real: the company remains unprofitable, and its shares already trade above the average analyst price target, with even the most bullish published target at $65. Investors should monitor Atera-related revenue growth, gross-margin trends, the path toward profitability, and whether the stock can decisively hold above its 52-week high. Until the market re-rates the business well beyond current analyst expectations, $100 remains an ambitious — not imminent — objective.

How I Monitor TXG with Tickeron Tools

For traders monitoring whether TXG can sustain its momentum toward higher price targets, I rely on Tickeron’s AI Daily Buy/Sell Signals. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. It helps me surface new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening alone allows.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TXG

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TXG in downward trend: 10-day moving average broke below 50-day moving average on November 02, 2026

The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 69 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 35 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for TXG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 212 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.142). P/E Ratio (-100.475) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a life science technology company, which engages in building products to interrogate, understand and master biology

Industry MedicalNursingServices

Industry
N/A
Address
6230 Stoneridge Mall Road
Phone
+1 925 401-7300
Employees
1178
Web
https://www.10xgenomics.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.